Vivolux’s mission is to explore new therapies against cancer. Our R&D projects are performed in close collaboration with cancer institutes and academia with very encouraging outcomes.
|At Vivolux we believe in the methodology and creativity of Ehrlich although since his time chemical know-how and the instruments found in pharmaceutical laboratories have advanced considerably. By combining creativity with expert knowledge in organic chemistry, biochemistry, clinical pharmacology, mechanism of action studies and experimental and clinical oncology, Vivolux is playing an active part in developing the magic bullets predicted by Ehrlich. Achieving success in the search for a 'magic bullet' in cancer therapy is now greater than ever.|
PRESS RELEASE | May 20, 2016
Vivolux announced today that dose level 4 of the ongoing VLX600 study has been successfully completed as part of its phase I/II study. Patient enrollment is now expanding to dose level 5, 90 mg of VLX600.More
PRESS RELEASE | September 17, 2015
Vivolux, a pharmaceutical company specialized in cancer treatment, announced today that the first patient in its ongoing Phase I/II study has successfully completed treatment at the third dose level of the drug candidate VLX1570.More
Vivolux's focus and strategy has led to the successful registration of two novel drug candidates. The clinical programs are being run in collaboration with the leading cancer institutes in the USA.